Special Advertising

Pivotal Therapeutics Inc. (PVO:CNX) Stock Quote

Detailed Quote for Pivotal Therapeutics Inc. (PVO:CNX)
$ 0.125   -0.02 (-13.79%) Volume: 324.5k 3:23 PM EDT Sep 23, 2014
Today 5d 1m 3m 1y more
Last Price
0.125
Change $
0.02
Change %
13.79%
Tick
  
Bid
0.105
Bid Size
10,000
Ask
0.125
Ask Size
5,000
Open
0.12
High
0.13
Low
0.02
Prev Close
0.145
Last Trade
3:23
Volume
324.5k
52 Wk Hi
0.24
52 Wk Low
0.02
Market Cap
11.49m
Ex-Div Date
N/A
Div Rate
N/A
Yield
N/A
Shares
91,916,277
EPS (TTM)
-0.06
PE Ratio
N/A
Exchange
CSE
News and Media for Pivotal Therapeutics Inc. (PVO:CNX)
Sector News | Topic News
News for Pivotal Therapeutics Inc. (PVO:CNX)
Tue, Sep 23, 2014
9:51 AM Pivotal Therapeutics Inc. reaches new 52-week Low - QuoteMedia
Mon, Sep 15, 2014
5:42 PM Pivotal Therapeutics Grants Incentive Stock Options - Canada Newswire
5:42 PM Pivotal Therapeutics Grants Incentive Stock Options - PR Newswire
Wed, Sep 10, 2014
3:29 PM Pivotal Announces Publication of a Clinical Trial Showing Beneficial Effects of VASCAZEN\u00AE In The Correction of Omega-3 Deficiency In Cardiovascular Patients - PR Newswire
1:49 PM Pivotal Announces Publication of a Clinical Trial Showing Beneficial Effects of VASCAZEN\u00AE In The Correction of Omega-3 Deficiency In Cardiovascular Patients - Canada Newswire
1:49 PM Pivotal Announces Publication of a Clinical Trial Showing Beneficial Effects of VASCAZEN\u00AE In The Correction of Omega-3 Deficiency In Cardiovascular Patients - PR Newswire
Mon, Sep 08, 2014
11:50 AM Pivotal Appoints Accomplished Healthcare and Investment Industry Veteran, Prakash Gowd, as Chief Financial Officer - PR Newswire
11:50 AM Pivotal Appoints Accomplished Healthcare and Investment Industry Veteran, Prakash Gowd, as Chief Financial Officer - Canada Newswire
Wed, Sep 03, 2014
2:59 PM Unique Vasoprotective and Antihypertensive Effects of VASCAZEN\u00AE's Formulation Presented at ESC Congress 2014 - PR Newswire
2:19 PM Unique Vasoprotective and Antihypertensive Effects of VASCAZEN\u00AE's Formulation Presented at ESC Congress 2014 - Canada Newswire
2:19 PM Unique Vasoprotective and Antihypertensive Effects of VASCAZEN\u00AE's Formulation Presented at ESC Congress 2014 - PR Newswire
Wed, Aug 27, 2014
3:19 PM Pivotal Therapeutics Announces Second Quarter Financial Results - Canada Newswire
3:19 PM Pivotal Therapeutics Announces Second Quarter Financial Results - PR Newswire
Tue, Aug 19, 2014
12:21 PM Scientific Data Supports Superiority of Pivotal's Unique Omega-3 Formulation - PR Newswire
11:03 AM Scientific Data Supports Superiority of Pivotal's Unique Omega-3 Formulation - Canada Newswire
11:03 AM Scientific Data Supports Superiority of Pivotal's Unique Omega-3 Formulation - PR Newswire
Wed, Aug 06, 2014
12:11 PM Pivotal Therapeutics To Explore Potential Commercial Partnership Opportunities in China - Canada Newswire
12:11 PM Pivotal Therapeutics To Explore Potential Commercial Partnership Opportunities in China - PR Newswire
Wed, Jun 11, 2014
10:34 AM Pivotal Therapeutics engages Kilmer Lucas for cross-border investor relations - Canada Newswire
10:34 AM Pivotal Therapeutics engages Kilmer Lucas for cross-border investor relations - PR Newswire
More News for PVO:CNX >>

Tags for Pivotal Therapeutics Inc.

Research stocks or mutual funds related to Pivotal Therapeutics Inc. by keywords or tags. Find companies that have a similar focus to PVO:CNX. The keywords below have been associated to PVO:CNX by either user submission or electronic means.